On Aug. 10, 2020, two Phase 3, randomized, placebo-controlled, double-blind clinical trials testing whether experimental monoclonal antibodies (mAbs) can prevent infection by SARS-CoV-2 coronavirus began enrollment of healthy adults at clinical trial sites in the U.S.<./p>

The trials are enrolling adults who are at risk of infection due to close contact at work or home to persons with SARS-CoV-2 infection.